Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal
infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp.,
and Mucorales fungi).